Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
187 hedge funds and large institutions have $587M invested in Catalyst Pharmaceutical in 2022 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 56 increasing their positions, 74 reducing their positions, and 13 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
177% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 13
31% more capital invested
Capital invested by funds: $447M → $587M (+$140M)
21% more call options, than puts
Call options by funds: $550K | Put options by funds: $454K
14% more funds holding
Funds holding: 164 → 187 (+23)
4.92% more ownership
Funds ownership: 64.02% → 68.95% (+4.9%)
24% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.9M |
| 2 |
Millennium Management
New York
|
+$6.59M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$6.21M |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$4.59M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$4.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$8.48M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.06M |
| 3 |
Aviva
London,
United Kingdom
|
-$2.61M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$2.47M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.42M |
CPRX Hedge Fund Activity: Q1 2022 in Review
187 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2022, worth a combined $587M — up 31% from $447M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CPRX positions and 13 closed out — a net gain of 23 holders — while 56 added to existing stakes and 74 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.9M. The largest seller was Armistice Capital, cutting an estimated $8.48M.
- 187 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2022, up from 164 in Q4 2021.
- Funds reported $587M of Catalyst Pharmaceutical stock for Q1 2022, up 31% quarter-over-quarter.
- 36 funds opened new Catalyst Pharmaceutical positions in Q1 2022 and 13 closed out, a net change of +23 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2022 was Morgan Stanley, an estimated $6.9M added.
- The largest Catalyst Pharmaceutical seller in Q1 2022 was Armistice Capital, an estimated $8.48M sold.
Based on aggregated 13F filings for Q1 2022.